Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Schlieren, Switzerland, dedicated to pioneering a new class of custom-built protein therapies known as DARPin therapeutics. The company's core mission is to address significant unmet medical needs, particularly in challenging diseases such as cancer and other serious conditions, by leveraging its proprietary DARPin platform.

The company's pipeline focuses on oncology, immuno-oncology, ophthalmology, and infectious diseases. Key product candidates include MP0712, a Radio-DARPin Therapy for small cell lung cancer and neuroendocrine tumors, and MP0317, a tumor-localized CD40 agonist for advanced solid tumors, both in clinical development. Molecular Partners also develops next-generation immune cell engagers, such as MP0533 for acute myeloid leukemia, and Switch-DARPins. Additionally, the company developed ensovibep, a COVID-19 antiviral therapeutic candidate, which was in-licensed by Novartis.

Recent notable developments include the publication of Phase 1 data for MP0317 in Nature Cancer in May 2026, demonstrating tumor-localized CD40 activation, and presentations at AACR 2026 for preclinical data on MP0632 and MP0712. Patrick Amstutz serves as the Chief Executive Officer. Molecular Partners maintains a strong market position as a clinical-stage biotech firm, actively advancing its DARPin platform through internal innovation and strategic collaborations with major pharmaceutical partners like Novartis, Orano Med, and Amgen.